Erratum: Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells (Cell Death and Disease (2014) 5 (e1142) DOI: 10.1038/cddis.2014.102);Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Zhang, J S ^a,b   Herreros Vilanueva, M ^a,c   Koenig, A ^a,d   Deng, Z ^a,e   De Narvajas, A A M ^a   Gomez, T S ^a   Meng, X ^a   Bujanda, L ^c   Ellenrieder, V ^d   Li, X K ^b   Kaufmann, S H ^a   Billadeau, D D ^a  

^a Information Technology   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; GSK 3; NF B; Pancreatic cancer; TNF ; TRAIL

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOENZYME; LY 2064827; PROTEIN BCL 2; PROTEIN BCL XL; SHORT HAIRPIN RNA; SIRTUIN 1; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BCL2L1 PROTEIN, HUMAN; BIRC3 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; I KAPPA B; INHIBITOR OF APOPTOSIS PROTEIN; NF-KAPPAB INHIBITOR ALPHA; PROTEIN BCL X; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR RELA; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL DEATH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; IC 50; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; I-KAPPA B PROTEINS; INHIBITOR OF APOPTOSIS PROTEINS; ISOENZYMES; MICE; NF-KAPPA B; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTEOLYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84897464445     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.341     Document Type: Erratum

References (57)

1. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009; 13: 1221-1227.
2. Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 2004; 1705: 27-41.
3. Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013; 169: 1723-1744.
4. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331.
5. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
6. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013; 332: 194-201.
7. Arlt A, Muerkoster SS, Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 2013; 332: 346-358.
8. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
9. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2010; 1805: 123-140.
10. Roder C, Trauzold A, Kalthoff H. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 2011; 90: 450-455.
11. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19: 5477-5486.
12. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20: 4258-4269.
13. Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 2013; 20: 858-868.
14. Siegmund D, Klose S, Zhou D, Baumann B, Roder C, Kalthoff H et al. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell Signal 2007; 19: 1172-1184.
15. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434-7439.
16. Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by upregulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006; 4: 715-728.
17. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5: 2251-2260.
18. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116(Pt 7): 1175-1186.
19. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79: 173-189.
20. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009; 8: 4032-4039.
21. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
22. Carbone C, Melisi D. NF-kappaB as a target for pancreatic cancer therapy. Expert Opin Ther Targets 2012; 16(Suppl 2): S1-S10.
23. Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T et al. Aberrant glycogen synthase kinase 3 beta is involved in pancreatic cancer cell invasion and resistance to therapy. PloS One 2013; 8: e55289.
24. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006; 12: 5074-5081.
25. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65: 2076-2081.
26. Shimasaki T, Kitano A, Motoo Y, Minamoto T. Aberrant glycogen synthase kinase 3beta in the development of pancreatic cancer. J Carcinog 2012; 11: 15.
27. Bang D, Wilson W, Ryan M, Yeh JJ, Baldwin AS. GSK-3alpha promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-kappaB. Cancer Discov 2013; 3: 690-703.
28. Wilson W3rd, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008; 68: 8156-8163.
29. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003; 2: 1215-1222.
30. Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B et al. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. PloS One 2012; 7: e41102.
31. Barrell WB, Szabo-Rogers HL, Liu KJ. Novel reporter alleles of GSK-3alpha and GSK-3beta. PloS One 2012; 7: e50422.
32. Pak C, Miyamoto S. A new alpha in line between KRAS and NF-kappaB activation? Cancer Discov 2013; 3: 613-615.
33. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12: 957-971.
34. Liu KJ, Arron JR, Stankunas K, Crabtree GR, Longaker MT. Chemical rescue of cleft palate and midline defects in conditional GSK-3beta mice. Nature 2007; 446: 79-82.
35. Zhou J, Freeman TA, Ahmad F, Shang X, Mangano E, Gao E et al. GSK-3alpha is a central regulator of age-related pathologies in mice. J Clin Invest 2013; 123: 1821-1832.
36. Arfeen M, Bharatam PV. Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements. Curr Pharm Des 2013; 19: 4755-4775.
37. Sun M, Zhou T, Jonasch E, Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochim Biophys Acta 2013; 1833: 1489-1497.
38. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NFkappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283: G204-G211.
39. Steinbrecher KA, Wilson W 3rd, Cogswell PC, Baldwin AS. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005; 25: 8444-8455.
40. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279: 39541-39554.
41. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K et al. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem; 279: 49571-49574.
42. Itoh S, Saito T, Hirata M, Ushita M, Ikeda T, Woodgett JR et al. GSK-3alpha and GSK-3beta proteins are involved in early stages of chondrocyte differentiation with functional redundancy through RelA protein phosphorylation. J Biol Chem 2012; 287: 29227-29236.
43. Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003; 278: 39583-39590.
44. O'Dea E, Hoffmann A. The regulatory logic of the NF-kappaB signaling system. Cold Spring Harb Perspect Biol 2010; 2: a000216.
45. Siggers T, Chang AB, Teixeira A, Wong D, Williams KJ, Ahmed B et al. Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-kappaB family DNA binding. Nat Immunol 2012; 13: 95-102.
46. Smale ST. Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol Rev 2012; 246: 193-204.
47. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol 2012; 34: 176-184.
48. Haag C, Stadel D, Zhou S, Bachem MG, Moller P, Debatin KM et al. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011; 60: 225-237.
49. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosisinducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65: 2344-2352.
50. Vogler M,Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425-2434.
51. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68: 7956-7965.
52. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16: 5734-5749.
53. Zhang JS, Koenig A, Young C, Billadeau DD. GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration. Mol Biol Cell 2011; 22: 2119-2130.
54. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013; 2: e61.
55. Zhang JS, Koenig A, Harrison A, Ugolkov AV, Fernandez-Zapico ME, Couch FJ et al. Mutant K-Ras increases GSK-3beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 2011; 30: 3705-3715.
56. Meng XW, Peterson KL, Dai H, Schneider P, Lee SH, Zhang JS et al. High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem 2011; 286: 35823-35833.
57. Zhang JS, Moncrieffe MC, Kaczynski J, Ellenrieder V, Prendergast FG, Urrutia R. A conserved alpha-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol Cell Biol 2001; 21: 5041-5049.